Infections induced by low-dose corticosteroids in rheumatoid arthritis: A systematic literature review

Joint Bone Spine

Volumn 77, Issue 3, 2010, Pages 246-251

  Ruyssen Witrand, Adeline ^a   Fautrel, Bruno ^b   Saraux, Alain ^c   Le Loët, Xavier ^d   Pham, Thao ^e  

^a AP HP université Paris V René Descartes ^*  (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c SERVICE DE RHUMATOLOGIE   (France)

^d ROUEN UNIVERSITY HOSPITAL   (France)

^e HÔPITAL DE LA CONCEPTION   (France)

Author keywords

Corticosteroids; Infection; Low dose; Rheumatoid arthritis; Side effect

Indexed keywords

CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG;

ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; COMORBIDITY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG INDUCED DISEASE; HERPES ZOSTER; HUMAN; INFECTION; INFECTION RISK; LOW DRUG DOSE; OSTEOMYELITIS; PNEUMONIA; POSTOPERATIVE INFECTION; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SEPTICEMIA; SYSTEMATIC REVIEW;

ADRENAL CORTEX HORMONES; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFECTION; RISK FACTORS;

EID: 77952674600     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2010.02.009     Document Type: Article

References (34)

1. Mitchell D.M., Spitz P.W., Young D.Y., et al. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum 29 (1986) 706-714
2. Symmons D.P., Jones M.A., Scott D.L., et al. Long-term mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 25 (1998) 1072-1077
3. Wolfe F., Mitchell D.M., Sibley J.T., et al. The mortality of rheumatoid arthritis. Arthritis Rheum 37 (1994) 481-494
4. van Albada-Kuipers G.A., Linthorst J., et al. Frequency of infection among patients with rheumatoid arthritis versus patients with osteoarthritis or soft tissue rheumatism. Arthritis Rheum 31 (1988) 667-671
5. Vandenbroucke J.P., Kaaks R., Valkenburg H.A., et al. Frequency of infections among rheumatoid arthritis patients, before and after disease onset. Arthritis Rheum 30 (1987) 810-813
6. Boerbooms A.M., Kerstens P.J., van Loenhout J.W., et al. Infections during low-dose methotrexate treatment in rheumatoid arthritis. Semin Arthritis Rheum 24 (1995) 411-421
7. Schnabel A., Burchardi C., and Gross W.L. Major infection during methotrexate treatment for rheumatoid arthritis. Semin Arthritis Rheum 25 (1996) 357-359
8. Feltelius N., Fored C.M., Blomqvist P., et al. Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Ann Rheum Dis 64 (2005) 246-252
9. Kroesen S., Widmer A.F., Tyndall A., et al. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford). 42 (2003) 617-621
10. Salliot C., Gossec L., Ruyssen-Witrand A., et al. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford) 46 (2007) 327-334
11. Wei L., MacDonald T.M., and Walker B.R. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 141 (2004) 764-770
12. Dale D.C., and Petersdorf R.G. Corticosteroids and infectious diseases. Med Clin North Am 57 (1973) 1277-1287
13. Piper J.M., Ray W.A., Daugherty J.R., et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 114 (1991) 735-740
14. van Staa T.P., Leufkens H.G., Abenhaim L., et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 39 (2000) 1383-1389
15. Stuck A.E., Minder C.E., and Frey F.J. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 11 (1989) 954-963
16. Burmester G.R., Mariette X., Montecucco C., et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis 66 (2007) 732-739
17. Hernandez-Cruz B., Cardiel M.H., Villa A.R., et al. Development, recurrence, and severity of infections in Mexican patients with rheumatoid arthritis. A nested case-control study. J Rheumatol 25 (1998) 1900-1907
18. Listing J., Strangfeld A., Kary S., et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 52 (2005) 3403-3412
19. Saag K.G., Koehnke R., Caldwell J.R., et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 96 (1994) 115-123
20. Smitten A.L., Choi H.K., Hochberg M.C., et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 57 (2007) 1431-1438
21. van der Veen M.J., van der Heide A., Kruize A.A., et al. Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis 53 (1994) 224-228
22. van Everdingen A.A., Jacobs J.W., Siewertsz Van Reesema D.R., et al. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 136 (2002) 1-12
23. Mazzantini M, Doveri M, Consensi A, et al. Incidence of adverse effects during long-term, low-dose glucocorticoid treatment of rheumatoid arthritis. Arthritis Rheum 2007;56 Suppl. Abstract [991].
24. Curtis J.R., Patkar N., Xie A., et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 56 (2007) 1125-1133
25. Schneeweiss S, Setoguchi S, Weinblatt ME, al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007;56:1754-64.
26. Wolfe F., Caplan L., and Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 54 (2006) 628-634
27. Jain A., Witbreuk M., Ball C., et al. Influence of steroids and methotrexate on wound complications after elective rheumatoid hand and wrist surgery. J Hand Surg [Am] 27 (2002) 449-455
28. Murata K., Yasuda T., Ito H., et al. Lack of increase in postoperative complications with low-dose methotrexate therapy in patients with rheumatoid arthritis undergoing elective orthopedic surgery. Mod Rheumatol 16 (2006) 14-19
29. Perhala R.S., Wilke W.S., Clough J.D., et al. Local infectious complications following large joint replacement in rheumatoid arthritis patients treated with methotrexate versus those not treated with methotrexate. Arthritis Rheum (1991) 146-152
30. Strangfeld A., Listing J., Herzer P., et al. Risk of Herpes Zoster in patients with rheumatoid arthritis treated with anti-TNF-α agents. JAMA 7 (2009) 737-744
31. Antonelli M.A., Moreland L.W., and Brick J.E. Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate. Am J Med 90 (1991) 295-298
32. Lin AN, Paget SA, eds. Principles of corticosteroid therapy, London: Arnold. 2002:285-306.
33. Baxter J.D. Minimizing the side effects of glucocorticoid therapy. Adv Intern Med 35 (1990) 173-193
34. Jick S.S., Lieberman E.S., Rahman M.U., et al. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 55 (2006) 19-26